Graduate Institute of Natural Products, College of Pharmacy, Kaohsiung Medical University, Taichung, Taiwan.
J Viral Hepat. 2012 May;19(5):364-70. doi: 10.1111/j.1365-2893.2011.01558.x. Epub 2011 Nov 24.
Chronic hepatitis C virus (HCV) infection ultimately leads to chronic hepatitis, hepatic cirrhosis and hepatocellular carcinoma (HCC). As the standard treatment is not completely efficacious, a safer and more effective agent against HCV infection needs to be developed. In this report, we demonstrated that 3-hydroxy caruilignan C (3-HCL-C) isolated from Swietenia macrophylla stems exhibited high anti-HCV activity at both protein and RNA levels at nontoxic concentrations, with an EC(50) value of 10.5 ± 1.2 μm. Combinations of 3-HCL-C and interferon-α (IFN-α), an HCV NS5B polymerase inhibitor (2'-C-methylcytidine; NM-107) or an HCV NS3/4A protease inhibitor (Telaprevir; VX-950) increased the suppression of HCV RNA replication. The results suggested that 3-HCL-C may be a potential anti-viral agent. We then demonstrated that 3-HCL-C interfered with HCV replication by inducing IFN-stimulated response element transcription and IFN-dependent anti-viral gene expression.
慢性丙型肝炎病毒（HCV）感染最终会导致慢性肝炎、肝硬变和肝细胞癌（HCC）。由于标准治疗并非完全有效，因此需要开发针对 HCV 感染更安全、更有效的药物。在本报告中，我们证明了从桃花心木茎中分离得到的 3-羟基卡鲁里烷 C（3-HCL-C）在非毒性浓度下在蛋白质和 RNA 水平上均表现出很高的抗 HCV 活性，EC（50）值为 10.5±1.2μm。3-HCL-C 与干扰素-α（IFN-α）、HCV NS5B 聚合酶抑制剂（2'-C-甲基胞苷；NM-107）或 HCV NS3/4A 蛋白酶抑制剂（特拉匹韦；VX-950）的联合使用增加了对 HCV RNA 复制的抑制作用。结果表明，3-HCL-C 可能是一种有潜力的抗病毒药物。然后，我们证明 3-HCL-C 通过诱导 IFN 刺激反应元件转录和 IFN 依赖性抗病毒基因表达来干扰 HCV 复制。
